Air Liquide Healthcare, leading company of the house of home respiratory therapies in Spain, successfully closed on July 4 the agreement acquired by Novalab Iberian, specialized in advanced products and services for diabetes.
In this way Air Liquide enters the diabetes market, mainly with solutions for insulin-dependent patients and continuous glucose monitoring systems, since it has incorporated into the third most important company in the sector with an important patient base, a positionRelevant in the market and a very focused business towards this sector, as the companies have reported in a press release.
Novalab, in addition to being a reference in diabetes, also has an important weight in cardiovascular or the cyclium of women, and since its foundation in 1997 has been a company committed to the well -being of diabetic people, providing reliable, simple, quality productsproven and at reasonable costs.Among them include insulin pumps, medical instrumentation, devices or diagnostic tools.
In addition, it is consolidated as a technological company that allows new developments in the field of diabetes, as well as in the improvement of the day -to -day patients through self -control or analysis tools.Its activity is extended to the entire Spanish territory.
"Thanks to this operation, Novalab's expertise about the diabetes market and the power of the Air Liquide group come together to create a structure much more than reinforced," says Alejandro García, from Novalab Iberian, after knowing the agreement.
For his part Philippe Ogé, general director of Air Liquide Healthcare in Iberia stressed that his company is present in the diabetes market in other European countries."Our experience within the group will allow us to integrate this new activity in our subsidiary in Spain, strengthen our leadership and complete our wide care offer for the hundreds of thousands of patients we attend in our country," he said.
